Mildronate enhances the action of coronary deglutants, some hypotensive drugs, cardiac glycosides.
Mildronate can be combined with prolonged forms of nitrates, other antianginal drugs, anticoagulants and antiaggregants, antiarrhythmics, diuretic and bronchodilators.
In view of the possible development of tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin (for sublingual use) and antihypertensive agents (especially alpha-blockers and short-acting forms of nifedipine).
How to take, intake and dosage
In connection with the possibility of developing an exciting effect, the drug is recommended to be applied in the first half of the day and not later than 17.00 (when taken several times a day).
With IHD (angina pectoris, myocardial infarction), chronic heart failure as part of complex therapy, the drug is prescribed by mouth at a dose of 0.5-1 g / day, the frequency of application is 1-2 times / day. The course of treatment is 4-6 weeks.
With dyshormonal cardiomyopathy, Mildronate, as part of a complex therapy, is administered orally at 500 mg / day. The course of treatment is 12 days.
With subacute disorders of cerebral circulation (stroke and cerebrovascular insufficiency) after the end of the course of injection therapy with Mildronate continue to take as a part of complex therapy inside by 0.5-1 g / day, applying the whole dose once or dividing it into 2 divided doses. The course of treatment is 4-6 weeks.
With chronic disorders of cerebral circulation, the drug is taken as a part of the complex therapy inside by 0.5 g / day. The general course of therapy is 4-6 weeks. Repeated courses are possible after consultation with a doctor (usually 2-3 times a year).
With reduced working capacity, mental and physical overstrain (including athletes) is prescribed orally 500 mg 2 times / day. The course of treatment is 10-14 days. If necessary, the therapy is repeated after 2-3 weeks.
Athletes are recommended to use 0.5-1 g 2 times / day before training. The duration of the course in the preparatory period is 14-21 days, during the competition – 10-14 days.
With an abstinence syndrome with chronic alcoholism (in combination with specific therapy of alcoholism), the drug is administered orally 500 mg 4 times / day. The course of treatment is 7-10 days.
Amount in a package
Symptoms: decreased blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.
Treatment: symptomatic therapy.
increased intracranial pressure (including with violation of venous outflow, intracranial tumors);
age under 18 years (effectiveness and safety not established);
lactation period (breastfeeding);
hypersensitivity to the active ingredient and other components of the drug.
With caution should apply the drug in diseases of the liver and / or kidney.
hemophthalmia and hemorrhage into the retina of various etiologies;
thrombosis of the central vein of the retina and its branches;
IHD of cerebral circulation;
Retinopathy of various etiologies (diabetic, hypertonic).
Application in pregnancy and lactation
The safety of the drug during pregnancy is not established. To avoid possible adverse effects on the fetus, do not prescribe Mildronate during pregnancy.
It is not known whether meldonia dihydrate is excreted in breast milk. If you need to use the drug Mildronate during lactation breastfeeding should be discontinued.
Hypersensitivity; increased intracranial pressure (with violation of venous outflow, intracranial tumors).
1 caps. Meldonium dihydrate 500 mg
Auxiliary substances: potato starch – 27.2 mg, silicon dioxide colloid – 10.8 mg, calcium stearate – 5.4 mg.
The composition of the capsule shell: titanium dioxide (E171) – 2%, gelatin – 98%.
Patients with chronic liver and kidney disease should be careful with prolonged use of the drug.
Use in Pediatrics
There is insufficient data on the use of Mildronate in children and adolescents under the age of 18 years.
Impact on the ability to drive vehicles and manage mechanisms
Data on the adverse effects of Mildronate on the ability to drive vehicles and mechanisms are not available.
Conditions of leave from pharmacies
In a dry place, at a temperature of no higher than 25 ° C